CoQ10 is a fat-soluble compound produced in the body that plays a central role in mitochondrial energy production (the electron transport chain) and functions as an antioxidant. Ubiquinol is the reduced, active form of CoQ10 most commonly found in premium supplements. Both forms have well-studied physiological roles and clinical research programs — which creates the characteristic supplement compliance challenge: scientifically interesting evidence that almost uniformly generates disease claims when marketed directly.
What FDA Permits for CoQ10 Claims
Under 21 CFR 101.93(f), permissible structure/function claims for CoQ10 and mitochondrial support supplements include:
"Supports healthy mitochondrial function"
"Promotes cellular energy production"
"Supports cardiovascular health"
"Promotes healthy heart muscle function"
"Supports healthy energy levels"
"Promotes antioxidant protection of cells"
"Supports healthy CoQ10 levels"
"Promotes healthy energy metabolism"
"Supports healthy aging at the cellular level"
These claims describe CoQ10's role in normal cellular energy production and antioxidant function. They don't imply treatment of heart disease, mitochondrial disorders, or statin-related conditions.
Where CoQ10 Claims Cross the Line
Prohibited disease claims:
"Treats heart failure" — congestive heart failure is a named disease; CoQ10 has been studied in CHF patients but treatment claims require drug approval
"For statin users with muscle pain" — statin-induced myopathy is a drug side effect/clinical condition; targeting this population implies treatment
"Corrects CoQ10 deficiency from statins" — deficiency in a disease/drug-interaction context implies treatment
"Reduces symptoms of mitochondrial disease" — mitochondrial diseases are named genetic conditions
"For people with cardiomyopathy" — named cardiac disease
"Improves cardiac output" — implies correction of a cardiac disease state
"Prevents statin side effects" — implies prevention of a drug-related adverse condition
The statin connection is the highest-risk context for CoQ10 claims
Statins deplete CoQ10 levels, and CoQ10 supplementation has been studied for statin-induced myopathy. This well-documented mechanism creates enormous claim risk — because any marketing that targets statin users specifically, or references CoQ10 depletion by statins, implies treatment of a drug side effect (a clinical condition). "Supports healthy CoQ10 levels in people on statins" falls directly into disease/drug-interaction treatment territory under 21 CFR 101.93(g)(2)(iv)(B), which treats drug reference claims as disease claims.
Ubiquinol vs. CoQ10: A Marketing Distinction With Compliance Implications
Ubiquinol is marketed as the "better absorbed" or "more bioavailable" form of CoQ10, commanding premium pricing. Structure/function claims about ubiquinol should reflect the same framework as CoQ10. Comparative claims ("ubiquinol is more bioavailable than ubiquinone") require substantiation under FTC Act Section 5 — there is evidence supporting better absorption in certain populations, but specific comparative claims require substantiation at the actual product dose and formulation.
Mitochondrial Supplement Claims Beyond CoQ10
The mitochondrial support category has expanded to include PQQ (pyrroloquinoline quinone), Alpha-lipoic acid, Acetyl-L-carnitine, and NAD+ precursors (NMN, NR) in mitochondrial formulations. Each of these ingredients carries its own claim framework:
PQQ: Emerging evidence for mitochondrial biogenesis support. Structure/function claims about promoting mitochondrial health may be potentially permissible. Claims about treating mitochondrial disease are not.
Alpha-lipoic acid: Established antioxidant evidence. Claims about supporting healthy antioxidant defense and metabolic function are potentially permissible. Claims about treating diabetic neuropathy (a named condition where ALA has been studied) are disease claims.
Acetyl-L-carnitine: Evidence for cognitive and energy support. Same framework applies — support for normal function is permissible; treatment of neurological disease is not.
CoQ10 claims require context-sensitive review — the statin connection and heart failure research create specific claim risks
Truli scans CoQ10 and mitochondrial supplement claims for statin-related disease targeting, heart failure treatment language, and mitochondrial disease claims — distinguishing between permissible cellular energy and cardiovascular support claims and the prohibited disease claim territory that CoQ10's clinical research history maps directly onto.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
